- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01348217
Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus (CONCORDE)
Prodige 26: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
Exclusive concomitant radiochemotherapy (RCT) at a dose of 50 Gy delivered over 5 weeks, according to the RTOG 85-01 protocol, has led to improved 5-year survival in 25% of patients, whereas no patients survived for 5 years using radiotherapy alone for patients with esophageal cancer. Surgery, even when combined with preoperative RCT, also gives disappointing results for locally advanced tumors, which casts serious doubts on the usefulness of preoperative radiotherapy. By varying the fractionation schedule, the length of treatment or the radiotherapy volumes, it has become possible to obtain levels of loco-regional relapse of around 35 to 45%. After reviewing the results for loco-regional relapse according to the dose of radiation and the recommended radiotherapy volumes, we aimed to investigate why increasing the dose of radiation has no impact in esophageal cancers. Although INT-0123 phase III trial showed no benefit of dose escalation in esophageal cancer, some issues remain unclear as most of the patients who died in the experimental arm were treated above 50Gy. Moreover, only the tumor was treated up to 64Gy while involved nodes were not considered for dose escalation in this trial. In the RTOG 85-01phase III trial, an elective nodal irradiation from subclavicular fossa up to the esophagogastric junction was performed with a 2D technique, delivering 30Gy which could be considered as not appropriate.
In this randomized phase II/III trial, we aim to test an exclusive concomitant chemoradiotherapy for patients with non resectable esophageal cancer with a dose escalation up to 66Gy on the primary tumor as well as the involved nodes using a 3D conformal technique combined with a 40 Gy elective nodal irradiation on lymph node stations (as defined by the RTOG) with a risk of microscopic involvement ≥ 20%.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Dijon, Frankrijk, 21000
- Centre Georges Francois Leclerc
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age> or = 18 and < 75 ans
- WHO Status 0, 1 and 2
- Enteral or parenteral feeding (> or = 1500 KCal) planned before the start of treatment
- Histologically proven carcinoma of the oesophagus
- Histological Types: adenocarcinomas and epidermoid carcinomas
- T3, N0-N1-N2-N3, M0 (TNM version 7)
- T1-T2, N0-N1-N2-N3, M0 with a contra-indication for surgery (TNM version 7)
- Absence of trachea-oesophageal fistula
- Written informed consent
- Woman under appropriate contraception
- Patient able to understand and complete, with help if necessary, a quality of life questionnaire
Exclusion Criteria:
- Evolutive heart failure or myocardial necrosis for less than 6 months
- Myocardial infarction of more than 6 months with ischemic sequelae on myocardial scintigraphy.
- Patient cannot absorb at least 1500kcal/j before and/or during treatment
- Left heart failure.
- Stage II to IV arteriopathy in the Leriche and Fontaine classification
- Creatinine > or = 1.25x N
- PNN < 1,5.109 /l
- Platelets < 100. 109 /l
- Albumin < 30g/l
- TP < 60% without anticoagulant
- VEMS < 1l
- History of cancer (except baso-cellular cutaneous epithelioma or in situ epithelioma of the cervix) that has relapsed in the 5 years preceding recruitment for the trial
- Patient already enrolled in another therapeutic trial with an experimental molecule
- Women who are pregnant or likely to be so, or who are breastfeeding
- People who are in custody or under guardianship
- Impossibility to adhere to the medical follow up for the trial for geographical,social or psychiatric reasons.
- Presence of a history of radiotherapy to the chest or upper abdomen for another tumour
- Peripheral neuropathy > or = grade 1 (CTC v3.0)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: ARM A
Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph nodes:
|
40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
Boost 10 Gy in 5 fr, PTV = +1cm.
Boost 26 Gy in 13 fr, PTV = +1cm.
6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
|
Experimenteel: ARM B
Conformal 3D Radiotherapy with " ENI "-type prophylactic irradiation of the lymph nodes:
|
40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
Boost 10 Gy in 5 fr, PTV = +1cm.
Boost 26 Gy in 13 fr, PTV = +1cm.
6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Evaluate the rate of acute toxicity leading to cessation or temporary interruption of treatment of more than a total of 14 days or of 7 consecutive days during the whole treatment.
Tijdsspanne: end of phase II (january 2014)
|
end of phase II (january 2014)
|
Evaluate the rate of completes endoscopic response at 3 months
Tijdsspanne: for each patient 3 months after the end treatment
|
for each patient 3 months after the end treatment
|
Survival without locoregional relapse at 2 years (time elapsed between date of randomisation and onset of local relapse and/or lymph node involvement)
Tijdsspanne: after the end of phase III in january 2015 (anticipated)
|
after the end of phase III in january 2015 (anticipated)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Evaluate adherence
Tijdsspanne: every 3 months until the end of phase II (january 2014)
|
every 3 months until the end of phase II (january 2014)
|
|
Evaluate acute toxicity at 3 months
Tijdsspanne: for each patient 3 months after the end treatment
|
for each patient 3 months after the end treatment
|
|
Evaluate death due to toxicity
Tijdsspanne: each month during all the study
|
each month during all the study
|
|
Evaluate quality of life (QLQ-C30 [annex n° 2] + OG25 [annex n° 3])
Tijdsspanne: after the completion of phase II (january 2014)
|
after the completion of phase II (january 2014)
|
|
Compare according to treatment arm :Quality of life (QLQ-C30 [annex n° 2] + OG 25 [annex n° 3])
Tijdsspanne: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :Overall survival
Tijdsspanne: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :Disease-free survival
Tijdsspanne: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :Acute and late toxicity according to the CTCAE version 3.0 scale
Tijdsspanne: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :The number of palliative interventions, the time to the first palliative intervention
Tijdsspanne: after the completion of phase III (january 2015-anticpated)
|
after the completion of phase III (january 2015-anticpated)
|
|
Compare according to treatment arm :The rate of dysphagia according to Atkinson's criteria
Tijdsspanne: after the completion of phase III (january 2015-anticipated)
|
after the completion of phase III (january 2015-anticipated)
|
|
Compare according to treatment arm :Survival without local recurrence in responders
Tijdsspanne: after the completion of phase III (january 2015-anticipated)
|
after the completion of phase III (january 2015-anticipated)
|
|
Compare according to treatment arm :Progression-free survival in non-responding patients
Tijdsspanne: after the completion of phase III (january 2015-anticipated)
|
after the completion of phase III (january 2015-anticipated)
|
|
Evaluation of the post-operative morbi-mortalities
Tijdsspanne: after the completion of phase III (january 2015-anticipated)
|
Evaluation of the post-operative morbi-mortalities (in 30 days) of the group of patients which will benefit from of a surgery of the tumoral residue.
|
after the completion of phase III (january 2015-anticipated)
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Gilles Créhange, MD, Centre Georges Francois Leclerc
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 0291-1crgi09
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Slokdarmkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten